Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEJ046A: Ancer plus palliative radiation and continued immune checkpoint inhibitor after ICI progression in NSCLC
jRCTs031200109Phase 2Active, not recruiting
- Sponsor
- North East Japan Study Group
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Z-100 in non-small cell lung cancer (NSCLC), sponsored by North East Japan Study Group. Primary endpoints: Safety and Progression-free survival rate at 9 months. Started Mar 2021; status: active, not recruiting.
02
Drugs
Z-100
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031200109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200109.